EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”. · 2018

Read EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. by Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6786777.txt.

Introduction

Schoemans and co-authors present a joint position statement on assessing graft-versus-host disease. This complication strikes after blood stem cell transplants, when donor cells attack the patient. Several international guidelines exist, and their overlap confuses daily practice. Experts from European, U.S., and international transplant bodies reviewed them together.

The group recommends the MAGIC criteria for acute disease and the NIH 2014 criteria for chronic disease. These are judged the most complete and detailed available. The statement adds consensus definitions for key terms used across the field. It also gives practical guidance for applying the criteria. A companion web application spreads the advice. Common standards should let studies be compared fairly.

Catalog record

CREATORSchoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6786777

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment By Helene M. Schoemans, Stephanie J. Lee, James L. Ferrara, Daniel Wolff, John E. Levine, Kirk R. Schultz, Bronwen E. Shaw, Mary E. Flowers, Tapani Ruutu, Hildegard Greinix, Ernst Holler, Grzegorz Basak Published in: Bone marrow transplantation DOI: 10.1038/s41409-018-0204-7 ABSTRACT Several international recommendations address the assessment of graft-versus-host disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by GvHD experts from the European Society for Blood and Marrow Transplantation (EBMT), the National Institutes of Health (NIH) and the Center for International Blood and Marrow Transplant Research (CIBMTR) reviews the existing guidelines for both acute and chronic GvHD, addresses potential confusions that arise in daily practice and proposes consensus definitions for many key terms. We provide a historical perspective on the currently available guidelines and recommend the Mount Sinai Acute GvHD International Consortium (MAGIC) criteria for acute GvHD and the NIH 2014 criteria for chronic GvHD as the most comprehensive and detailed criteria available. This statement also offers practical guidance for the implementation of these recommendations and a set of consensus definitions for commonly used GvHD terms in order to facilitate future clinical and translational research. To assist the dissemination of these recommendations, a web-application based on this position statement is available (https://www.uzleuven.be/egvhd). We believe that adherence to a common set of GvHD assessment criteria is vitally important to improve the quality of data, compare results of retrospective studies and prospective clinical trials, and make therapeutic recommendations based on quality evidence. INTRODUCTION Graft-versus-host disease (GvHD) refers to a clinical syndrome caused by the response of transplanted donor allogeneic cells to histocompatibility antigens expressed on tissues of the transplantation recipient. It is the most serious complication of allogeneic hematopoietic cell transplantation (HCT). Its recognition and control are key elements of a successful outcome. In fact, the World Health Organization stipulates that data collection and data analysis are integral parts of therapy [1]. In practice, however, the application of basic concepts pertaining to the diagnosis and staging of this condition differs widely among HCT clinicians. The use of the templated data collection forms (such as those used by the Center for International Blood and Marrow Transplant Research (CIBMTR), the European Society for Blood and Marrow Transplantation (EBMT), and the National Institutes of Health/National Cancer Institute (NIH/NCI)) improves standardization by collecting data elements as proposed by published consensus documents but demands significant time from healthcare professionals and researchers. Several studies have shown a lack of adherence to recommendations and inconsistencies in GvHD evaluation [2–9]. Weisdorf et al. showed in one multi-center study that acute GvHD (aGvHD) grading at HCT centers significantly underestimated disease severity compared to a central, expert review board, with inaccurate evaluation of grade III GvHD in 18% of cases [7]. In a recent chronic GvHD (cGvHD) intervention trial, up to 10% of patients entered by GvHD Consortium centers were excluded from study analysis post hoc due to failure to meet diagnostic criteria at the time of inclusion [8]. Such discrepancies are concerning because they can significantly affect the interpretation of GvHD data in clinical trials. Misclassifications have been observed even among experienced HCT and GvHD professionals, and inaccuracies are therefore likely to be even more prominent among less experienced centers. In fact, a recent survey of practice patterns completed by transplant professionals during the annual 2017 EBMT conference showed wide variations in the types of reference guidelines used for GvHD assessments, and up to one third of the survey participants reported a lack of confidence in their ability to apply these guidelines [9]. Of interest, the GvHD assessments of two clinical vignettes became much more consistent and compliant with recent international guidelines when the same cases were evaluated using an electronic tool, the eGvHD App [9] (available at https://www.uzleuven.be/egvhd). The use of electronic tools to streamline and increase the reliability of the GvHD evaluation process has been advocated by several groups [4, 9–12], but such tools require a clear and broad consensus regarding reference guidelines to guarantee their internal validity. GvHD experts from the EBMT, NIH, and CIBMTR have therefore joined forces to: (1) review the existing guidelines for both acute and chronic GvHD and recommend those best supported by clinical evidence; (2) address confusions that arise in real-life scenarios encountered in clinical practice; and (3) develop consensus definitions for key terms frequently used in the evaluation and monitoring of GvHD. All three issues were addressed during a series of conference calls and manuscript draft reviews between May and October 2017. The mission of this effort is to advance GvHD research through a transparent and unbiased standardization of common elements in GvHD terminology, thereby increasing the quality and precision of the data collected in HCT clinical research and practice. ISSUE 1: STANDARDIZED ASSESSMENTS OF GVHD: A HISTORICAL PERSPECTIVE Acute GvHD definition Acute GvHD refers to the appearance of an allogeneic inflammatory response in exclusively three organs: the skin (inflammatory maculopapular erythematous skin rash), the liver (hyperbilirubinemia due to cholestatic jaundice), and the gastro-intestinal (GI) tract (upper and/or lower GI tract manifestations: anorexia with weight loss, nausea, vomiting, diarrhea, severe pain, GI bleeding and/or ileus) [13–16]. The diagnosis must occur in the absence of manifestations of cGvHD [17, 18] (Fig. 1a) and should ideally be supported by positive histological findings, but this is not strictly necessary if no alternative etiology is present. The Glucksberg aGvHD classification was first proposed in the 1970s based on a cohort of 60 patients evaluated for aGvHD after myeloablative conditioning. This classification staged skin, lower gastrointestinal tract and liver, each on a scale of 0 (absent) to 4 (severe) points (Table 1), to create a final overall grade of I (mild) to IV (life-threatening) [13]. The overall aGvHD grade typically corresponds to the highest grade conferred by the individual staging of each organ, as described in Table 2. Approximately 20 years later, the Keystone aGvHD consensus panel reviewed the outcome of the Glucksberg classification in almost 6000 patients and confirmed the predictive value of maximum aGvHD grade for day 100 mortality [14]. Three major recommendations that resulted from that review were: (1) upper GI tract manifestations, in the presence of a positive biopsy, should be classified as overall grade II aGvHD; (2) GI stage 4 should be based on severe symptoms such as severe pain, bleeding and/or ileus and not diarrhea volume; and (3) functional status should be eliminated as an element of overall grade because of its non-specific and multi-factorial etiology. In parallel, the CIBMTR proposed the IBMTR aGvHD classification: this alternative algorithm was based on similar raw organ staging (Table 1) and resulted in a final grade of A–D (Table 2), which provided a slightly more accurate prediction of mortality [15]. Recently, MacMillan and colleagues published a further adaptation of the Keystone consensus criteria: the Minnesota aGvHD grading, which limited overall grade IV aGvHD to skin and gut stage four, instead of skin and liver stage four as described in the Keystone criteria [19] (Table 2). In this study, no particular grading system was superior in predicting survival. The availability of these different options to assess aGvHD can give rise to controversy when healthcare professionals do not clearly define which

Read the complete text